Carbiotix strengthens management team and adds CFO
Carbiotix (publ) ("Carbiotix") announces today that Henrik Ljung will start as Chief Financial Officer (“CFO”) for the company on the 1st of April, thereby strengthening the management team and providing key knowledge and experience to capitalise on the company’s strategic position and growth opportunities. Henrik brings with him many years of experience working as CFO in a number of listed companies in Sweden.
Born in 1958, Henrik Ljung holds a business administration (Civilekonom) degree from Lund University and has many years of experience working as CFO for, among others, Lumito AB, SpectraCure AB, Acconeer AB, AB Sardus and Malmöhus Invest AB.
Kristofer Cook, CEO for Carbiotix, comments
“I am extremely pleased that Henrik has decided to join our team as we ramp up our development and sales activities. He joins at a time when we have announced accelerated plans to market with regards to our prebiotic ingredient and medical food modulator, and very good market traction in the diagnostics business area. Henrik joining will not only fulfill a commitment we made to strengthen our management team during the IPO process, but will provide key knowledge and experience to capitalise on our strategic position across all business areas. I look forward to constructively interacting with Henrik in the months and years to come to achieve sustained profitability in the shortest possible time frame while investing to further strengthen our competitive position in the market.”
Henrik Ljung, CFO for Carbiotix, comments
“Carbiotix is a very exciting company in the life science area and pioneer with regards to microbiome healthcare, targeting both diagnostics and modulators. The company is very well positioned to capture significant value from several multi-billion Euro markets and I will do my best to assist the company in this regard. I look forward to making a positive contribution to the management team and helping the company generate long-term shareholder value.”
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company’s contact person set out below on 9 March 2020.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
For further information:
Kristofer Cook, CEO
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.